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CD25 Expression Is Correlated with Histological
Grade and Response to Denileukin Diftitox
in Cutaneous T-Cell Lymphoma
Rakhshandra Talpur1, Daniel M. Jones2, Alvaro J. Alencar1, Narin Apisarnthanarax1, Kelly L. Herne1,
Ying Yang3 and Madeleine Duvic1
Denileukin diftitox (Ontaks), a recombinant fusion protein of diphtheria toxin and ligand, IL-2, binds to the IL-2
receptor, is internalized, and causes cell death. Denileukin diftitox was approved for the treatment of cutaneous
T-cell lymphomas (CTCLs) with CD25þ expression. We prospectively stained lesional skin biopsy specimens
from 113 mycosis fungoides and Se´zary Syndrome patients for activation markers CD25 and CD30 to correlate
expression with clinical tumor-node metastasis (TNM) stage, histologic grade, and response to denileukin
diftitox. High expression was defined as positivity of X20% of lesional T-cells using immunohistochemistry
(IHC). CD25 and CD30 expression was more common in lesions from advanced patients (P¼ 0.04 and 0.002,
respectively). Advanced TNM (T3 or T4) was significantly associated with intermediate-grade (P¼ 0.002) and
large-cell transformation histology (P¼ 0.04). Of interest, clinical responses were observed in 78.5% of patients
with high CD25 expression versus 20% with low to undetectable CD25 expression (P¼ 0.01) among 24 patients
receiving standard 5-day infusions of denileukin diftitox at 18 mg/kg/day. These data suggest that high CD25
expression by IHC is associated with advanced CTCL and with clinical response to denileukin diftitox therapy.
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INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) include several distinct
entities that have been defined by their clinical presentation
and expression of cell surface markers determined by
immunohistochemistry (IHC) staining (Willemze et al.,
1997; Jaffe et al., 2001). The term CTCL is often used
synonymously for mycosis fungoides (MFs) and the leukemic,
erythrodermic variant, Se´zary syndrome (SS), the most
commonly encountered CTCLs (Kim and Hoppe, 1999). In
MF one or more clonal populations of atypical CD3þ
CD4þCD45ROþ helper/memory T-lymphocytes with
defective activation-induced cell death accumulate in the
skin (van Doorn et al., 2000; Washington et al., 2002; Jones
and Duvic, 2003). Pleomorphic skin lesions in MF patients
include patches, plaques, papules, erythema, follicular
papules, tumors, alopecia, and changes in pigmentation,
whereas SS is defined as exfoliative erythroderma with
circulating atypical T-cells. Erythroderma and T-cell expan-
sion can be exacerbated by staphylococcal colonization in SS
(Jackow et al., 1997). Lymph nodes, bone marrow, or visceral
organs can become involved in the late stages. Epidermo-
tropism of MF is lost in SS, and the latter is defined by the
presence of 41,000 circulating atypical T cells (Vonderheid
et al., 2002) or by a clone of CD4þCD26 lymphocytes on
flow cytometry (Jaffe et al., 2001; Washington et al., 2002).
Although many patients with MF have an indolent course,
large-cell transformation (LCT), defined as more than 25%
large cells in skin lesions or nodes, is associated with
decreased survival if it appears within 2 years of diagnosis
(Diamandidou et al., 1999). A spectrum including the self-
regressing lymphomatoid papulosus, primary cutaneous, and
systemic anaplastic large-cell lymphomas express CD30, an
activation marker, first described in Reed–Sternberg cells (Lui
and Janeway, 1990).
MF and cutaneous anaplastic large-cell lymphoma are
often indolent in the early stages, thus skin involvement is
managed by skin-directed therapy. Early chemotherapy is not
curative and may lead to progression owing to damage to the
intrinsic host antitumor immunity (Apisarnthanarax et al.,
2002). In the face of refractory disease or disease progression,
biological response modifiers such as bexarotene, an
approved RXR-selective retinoid (Duvic et al., 2001a, b),
and cytokines such as interferons (a or g) and IL-12
are effective as single agents or in combination with
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phototherapy or photopheresis (Rook et al., 1999; Vittorio
et al., 2001).
Unique surface tumor markers, especially the T-cell
receptor, are attractive targets for safe and selective antitumor
therapy such as antibodies or ligands coupled to a fusion
toxin, of which IL-2 and diphtheria toxin is the first approved
prototype (Olsen et al., 2001; Foss and Waldmann, 2003).
The IL-2–diphtheria toxin fusion protein, denileukin diftitox
(DAB389IL-2, Ontak
s; Ligand Pharmaceuticals Inc., San
Diego, CA), was approved for the treatment of CTCL in
February 1999 (Olsen et al., 2001). In the two clinical trials,
denileukin diftitox was administered only to refractory CTCL
patients whose skin lesions hadX20% CD25 expression on a
frozen section stained by IHC, thus its efficacy for patient
with lower CD25 expression has not been evaluated.
Furthermore, a fixed-tissue IHC assay for determining CD25
expression and response to denileukin diftitox has not been
established previously.
When denileukin diftitox binds to high or intermediate-
affinity IL-2 receptors (IL-2R) on T-cells, this is followed by
internalization and cell death through inhibition of adenosine
diphosphate ribosylation of elongation factor 2 (Foss, 2000).
The high-affinity IL-2R is a complex consisting of two obligate
subunits: IL-2Rb (CD122, p75) and -g (CD132, p64), and a
variably expressed IL-2Ra subunit (CD25, p55). The p55
protein or CD25 alone defines a low-affinity IL-2R, p75 and
p64 define an intermediate-affinity IL-2R, and all three are
required for the high-affinity IL-2R (LeMaistre et al., 1992,
1998). Although denileukin diftitox binds to all three forms of
the IL-2R, only cells with the intermediate- or high-affinity
receptors will internalize the fusion protein (Waters et al.,
1990).
As denileukin diftitox in clinical trials was restricted only
to patients whose skin biopsies demonstrated X25%
positivity for CD25 on a fresh–frozen tissue assay at a
reference laboratory, we decided to compare local frozen
and paraffin-fixed assays for CD25 and to ascertain prospec-
tively the prevalence of expression of two activation markers,
CD25 and CD30, in CTCL patients. CD25 and CD30
expression was analyzed with respect to patients’ tumor-
node metastasis (TNM) stage and histological grade of CTCL.
Secondly, we prospectively addressed whether the level of
CD25 expression in skin biopsies was a useful marker to
predict clinical response to denileukin diftitox therapy.
RESULTS
Patients
One hundred thirteen patients with MF (n¼100) and/or SS
(n¼13) were studied for CD25 and CD30 expression in
lesional skin biopsies. There were 57 males and 56 females,
with a median age of 66 years (range, 12–84 years). Sixty-four
patients were classified as early MF (T1, T2) and 49 had
advanced clinical status (T3, T4), including 13 who had
erythroderma and blood involvement characteristic of SS.
Forty-eight individuals had newly diagnosed MF or SS, and
54 had been recently diagnosed and staged, but had received
skin-directed treatment (topicals or UVB therapy) without any
change in T status. At the time of skin biopsy evaluation, 11
additional T1 patients progressed to T3 (n¼7) or T4 (n¼ 3)
plus one T1 and one each of the T3 and T4 patients
developed new nodes (Table 1). High CD25 and positive
CD30 expression in individual patients across the clinical
range of early to advanced MF/SS are shown in scatter plots
(Figure 1).
High CD25 and positive CD30 expression in lesional biopsy
specimens correlates with T status and histological grade of
CTCL
Twenty-four (22%) of 113 CTCL patients’ skin biopsies
contained 420% lymphocytes with CD25þCD3þ T-cells
at baseline. As shown in Figure 1a, patients with expression
of CD25 were encountered at all T stages of MF and SS
without significant differences. In early-stage patch/plaque
(T1, T2) MF lesions, CD25 immunostaining was limited to the
epidermotropic T-cells at the dermal–epidermal junction
(Figure 2a) or in the epidermis including Pautrier’s micro-
abscesses (Figure 2b). Considering early MF (T1, T2) versus
advanced MF (T3, T4) and SS, 33% (16/49) of the T3, T4
patients’ lesions had high CD25 expression (420% CD25þ
T-cells) compared to only 13% (8/64) in T1 or T2 lesions
(P¼0.04).
With respect to histological progression, ‘‘LCT’’ was
defined as 425% large cells and intermediate progression
was defined as 10–25% large cells within a lesion. Of 49 T3,
T4 patients, 14 had skin lesion histology compatible with LCT
and eight demonstrated intermediate histology. Two of the 14
patients’ skin biopsies had initial small cells with transfor-
mation to increased large cells in later biopsy specimens. In
12 patients, lesional biopsies displayed increased numbers of
large cells at the time of initial evaluation. Of the eight
patients’ biopsies that showed intermediate LCT, five
represented transformation from small cells on initial
biopsies. Increased CD25 expression was seen in eight of
14 lesional skin biopsies with LCT and in four of eight with
intermediate LCT. Seven of 14 lesions (50%) with a
predominance of large cells contained 440% of lympho-
cytes staining positive for CD25 expression. As shown in
Figure 3, the larger lymphocytes in the lesions are pre-
dominantly positive for CD25þ immunostaining.
Positive CD30 expression (defined as 410% CD30þ
immunostaining at baseline) was significantly more frequent
among 10 of 49 (20%) T3, T4 patients’ lesional skin biopsies
(P¼0.003) (Figure 1b) than T1 or T2 patients’ lesions, only
two of which were positive. CD30 expression of 425% was
observed in two T4 and one T3 patients’ skin lesions. Of the
12 CD30þ patients, one T1 patient had a partial response to
treatment, whereas six T3 and three T4 patients progressed.
Co-expression of CD25 and CD30 were not present in T1 or
T2 MF lesions, but was observed in four of 49 (8%) of T3 or
T4 lesions (P¼0.04). The presence of one or the other
activation marker was more frequently seen in advanced MF
patients 45% (22/49) compared to early MF T1–2 lesions 14%
(9/64) (P¼ 0.002). Positive CD30þ expression (410%) was
significantly associated with transformed MF with 425%
large cells (Po0.01).
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High CD25 expression in skin lesions at baseline is associated
with response to treatment with denileukin diftitox
To determine whether high expression levels of CD25 in
lesional skin biopsy specimens were predictive of response to
denileukin diftitox, baseline skin lesions from 24 advanced
stage CTCL patients were studied by IHC. Half of the patients’
biopsy specimens were by a frozen and half were by a fixed-
tissue, paraffin-embedded IHC assay (Jones et al., 2004;
Tables 3a and b). The patients (Table 2) were considered for
treatment with denileukin diftitox, without prior knowledge
of their CD25 status (Tables 3a and b). Sixteen patients’
lesional biopsies were bisected and one-half was sent
to the reference lab and the other evaluated locally (Table
3c). As shown in Table 2, 11 patients received 5-day cycles of
daily infusions at a dose of 18 mg/kg/day. Two patients
received only 9 mg/kg/day and eight patients started with a
dose of 9 mg/kg/day during their first course and had increased
dose levels during subsequent treatment cycles. Three
patients started at 18 mg/kg/day but received subsequent
therapy at the lower dose. Patients were treated with
denileukin diftitox until they progressed, had dose limiting
toxicity, or failed to improve after three cycles. Responses
were judged by modified skin assessment tool as described
(Olsen et al., 2001) and duration of response is shown for
patients with response confirmed for at least one cycle.
Denileukin diftitox was administered for 1–16 cycles (median
– three cycles). The median number of cycles given to
patients with high CD25 expression was 5 (range 2–16) versus
patients with low CD25 expression was 2.5 cycles (range
(1–3). Patients were taken off therapy for disease progression
or if they failed to have a minor response by 3 months. No
patients in either group had a complete response. Twenty-
two of 24 patients received low-dose prednisone premedica-
tion therapy and 11 of 22 experienced vascular leak
syndrome as defined by edema, low blood pressure, and
low albumin.
Fourteen of 24 (58%) patients treated with denileukin
diftitox had high CD25 expression (X20% of lesional
T-cells), six patients had intermediate levels of CD25
expression (5–19% of T-cells), and four had minimally
detectable expression (o5% lesional T-cells) (Tables 2 and
3a–c). Of 14 patients with high CD25 expression, 11 of 14
(79%) experienced a partial response, and three had stable
disease (95% confidence interval is (0.52–0.93)). In contrast
to patients with high CD25 expression, only 20% (two of 10)
patients with intermediate to low CD25 expression in their
baseline biopsies had partial responses (P¼0.01). Among
those patients with low expression, seven had stable disease,
and one progressed on therapy. Among six patients with
histologic LCT, three of six (50%) experienced partial
response, two had stable disease, and one had progressive
disease.
Table 1. TNM status of 113 CTCL patients at baseline or following skin-directed therapies
Previously treated N=65
Total CTCL
patients, N=113
Stage and TNM
status
Baseline untreated,
N=48 Male Female Stable, N=54
Progressed1,
N=11 Male Female
33 IA –(T1) 21 12 9 12 0 4 8
29 IB (T2) 10 3 7 19 0 8 11
2 IIA (T2) 1 1 0 1 0 0 1
24 IIB (T3) 9 5 4 9 6 10 5
6 III (T4) 2 1 1 2 2 3 1
11 IVA 3 3 0 5 3 3 5
1 IVA (T1N3B0) 0 0 0 0 1 0 1
1 IVA (T2N3B0) 0 0 0 1 0 1 0
1 IVA (T3N3B0) 0 0 0 0 1 0 1
2 IVA (T4N3B0) 1 1 0 0 1 1 0
3 IVA (T4N3B2) 1 1 0 2 0 0 2
3 IVA (T4N0B2) 1 1 0 2 0 1 1
8 IVB 2 1 1 6 0 4 2
1 IVB (T2N0M1) 0 0 0 1 0 1 0
2 IVB (T4N4B2M1) 1 0 1 1 0 0 1
5 IVB (T4N0B2M1)- 1 1 0 4 0 3 1
CTCL=cutaneous T-cell lymphomas; TNM=tumor-node metastasis.
1Eleven patients who progressed from baseline stage of IA or 1B (T1 or 2) to T3 or T4 or to LN3 were studied by biopsy at the time of T or LN progression.
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Lack of correlation of level of CD25 expression between labs
Sixteen patients had bisected lesional biopsy specimens
submitted to both the reference lab as snap-frozen specimens
or to MD Anderson Cancer Center lab as frozen (n¼ 5) or
fixed tissue (n¼11) for detection of the level of CD25
expression. As shown in Table 3c, five specimens showed
low CD25 expression, two showed high expression, and nine
were discordant. Overall, the correlation was poor between
the two laboratories (k values 0.31 and 0.29). Only five of
16 patients received denileukin diftitoxin: two partial
responsders with high CD25 expression by the reference
lab, one stable disease with high expression, and two stable
disease with low expression.
CD25 expression in lesional T-cells following treatment with
dileukin diftitox or oral bexarotene
Ten of 24 patients had post-treatment biopsy specimens for
CD25 expression after treatment. Of seven patients with high
baseline CD25 expression, four had low to absent expression
after treatment and three continued to exhibit high CD25þ
expression. Three patients with low to absent CD25 expres-
sion were studied and biopsies from two remained negative
and one (patient 2) showed higher CD25 expression
following treatment (Table 2). Although no correlation can
be made between baseline and post-treatment expression of
CD25 in skin biopsies among this small series of patients, loss
of CD25 expression in previously positive patients did
precede progression in several individuals, as illustrated in
Figure 4.
Foss et al. (2005) have recently reported that administra-
tion of oral bexarotene may increase CD25 expression in
blood cells. In our study, 15 patients receiving 300 mg/m2/
day of oral bexarotene therapy had evaluation of CD25
expression in lesional skin biopsies taken from the same
location at baseline and following several months of oral
bexarotene therapy. Two of 13 expressed 420% CD25 at
baseline, and both showed lower levels of expression post-
therapy. Only four of 15 patients’ lesional biopsy specimens
demonstrated upregulation of CD25 following oral bexaro-
tene therapy: one complete responder to bexarotene went
from 1 to 35% expression, two changed from 5 to 20%, and
one from 5 to 10%. Nine other patients’ biopsy specimens
had decreased or unchanged levels of CD25 expression
following oral bexarotene.
Lack of correlation between serum IL-2R levels or lactate
dehydrogenase and response to denileukin diftitox
Soluble IL-2R levels were measured in baseline serum
samples in 22 of 24 patients treated with denileukin diftitox
with values for each patient shown in Table 2. Thirteen (54%)
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Figure 1. Expression levels of activation marker by clinical stages. (a) Scatter
plot of individual patients (J) at each T stage with the level of CD25
expression in lesional biopsy. (b) Scatter plot of individual patients’ (J) CD30
expression (%) by clinical status. m, the mean of CD25 or CD30 expression
level at each T stage. K, the median of CD25 or CD30 expression level at
each T stage. The horizontal line is a cutoff at 20% of lymphocytes staining for
each marker.
a b
Figure 2. Immunohistochemical staining for CD25 in lesional MF biopsy
specimens. CD25þ lymphocytes are present (a) at the dermal/epidermal
interface (original magnification:  100) and (b) in a Pautrier’s microabscess
in the epidermis (original magnification: 600).
a b
Figure 3. Mycosis fungoides lesion with histologic large-cell transformation.
(a) Tumor cells have variable CD25 immunoreactivity on paraffin sections
(original magnification:  100). (b) CD25 expression is selectively upregu-
lated in large-cell component (arrows) and in the epidermotrophic tumor cells
(defined by the brackets) (original magnification:  600).
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Table 2. Demographics, treatment course, lesion histology, surrogate markers, and clinical response of patients
receiving denileukin diftitox therapy
Pt. no
Baseline
stage TNM Sex
Age
(years)
No. of
cycles
Dose
(lg/kg)
Best
response
Duration of
response
(weeks)
Baseline %
CD25+ Histology
F/U %
CD25+ Histology
Baseline
sIL-2R
Baseline
LDH
1 IIB/T3 M 68 1 18 PD N/A 1 FR LCT N/A N/A 5,868 NA
2 IIB/T3 F 42 3 18 SD N/A 5 FX UT 30 UT 2,639 814
3 IIB/T3 F 34 3 18 SD N/A 10 FX ILC 1 UT 1,409 761
4 IIB/T4 F 54 2 9/18 SD N/A 35 FR LCT N/A N/A 23,174 563
5 IIB/T3 M 59 8 18/9 PR 12 40 FX ILC N/A N/A 3,346 554
6 IIB/T3 F 82 2 18/9 SD N/A 50 FX ILC N/A N/A 1,042 462
7 IIB/T3 M 83 2 18/9 PR 8 60 FR LCT 50 LCT 1,251 343
8 IIB/T3 F 51 2 18 PR 4 95 FR UT N/A N/A N/A 593
9 III/T4 M 69 1 18 SD N/A 5 FR UT N/A N/A 5,868 1,580
10 III/T4 M 76 2 9/18 PR 4 15 FX UT N/A N/A 3,480 506
11 III/T4 M 56 4 9/18 PR 4 40 FX ILC 1 LCT 1,322 622
12 III/T4 M 72 4 18 PR 4 75 FR LCT 5 LCT 8,059 818
13 III/T4 F 65 2 9 SD N/A 20 FR ILC N/A N/A 28 792
14 IVB/T4IVA/ F 40 6 18 PR 4 30 FX LCT 5 UT 3,885 1,479
15 T1N3 F 67 1 9 SD N/A 5 FR ILC N/A N/A 8,476 1,529
16 IVA/T4N3 M 71 3 9/18 PR 8 10 FX ILC N/A N/A 941 477
17 IVA/T4B2 F 79 1 18 SD N/A 10 FR LCT N/A N/A 851 1,296
18 IVA/T4B2 F 41 3 18 SD N/A 15 FX UT 5 LCT 895 926
19 IVA/T3N0 F 60 8 18 PR 12 30 FX UT 50 UT N/A 494
20 IVA/T4N3 M 74 6 9/18 PR 8 40 FX UT N/A N/A 857 688
21 IVA/T4N3B2 F 65 16 9/18 PR 12 50 FX UT 10 UT 1,562 764
22 IVA/T3N3 M 57 8 9/18 PR 12 60 FX ILC N/A N/A 1,626 810
23 IVB/
T3N3M1
F 20 3 18 SD N/A 10 FX UT N/A N/A 1,926 671
24 IVB/
T2N0M1
M 66 7 9/18 PR 8 50 FR UT 75 UT 1,238 229
Patient’s baseline staging and current TNM status are both shown in column 2.
F=female; FR=frozen-tissue immunohistochemistry assay; FX=fixed-tissue immunohistochemistry assay; F/U=follow-up; ILC=intermediate large cell;
LCT=large-cell transformation; LDH=lactate dehydrogenase; M=male; N/A=not available; PD=progressive disease; PR=partial response; Pt.=patient;
SD=stable disease, sIL2-R=serum interleukin-2 receptor, w/-=with.
Table 3a. Response to denileukin diftitox based on the
level of CD25 expression in frozen versus fixed
lesional biopsy specimens
Low expression, frozen tissue
assay:
High expression, frozen tissue
assay:
1 PD, 4 SD=0/5 responders SD, SD, PR, PR, PR, PR=4/6
responders
Low expression, fixed tissue
assay:
High expression, fixed tissue
assay:
3 SD, 2 PR=2/5 responders1 2 SD, 6 PR=6/8 responders
Lesions from 24 patients were fixed in formaldehyde or frozen and the
expression of CD25 was by an immunohistochemistry assay.
PD=progressive disease; PR=partial response; SD=stable disease.
1Two PRs had 10 and 15% expression.
Table 3b. Level of CD25 and CD30 expression in 24
CTCL patients’ baseline lesions correlated with clinical
response to denileukin diftitox irregardless of local
IHC method
Level of CD25
expression
Low expression,
o20%
High expression,
X20%
Number of patients 10 14
PR 2/10 (20%) 11/14 (78.5%)
SD 7/10 (70%) 3/14 (21.5%)
PD 1/10 (10%) N/A
CTCL=cutaneous T-cell lymphomas; N/A=not applicable; PD=progressive
disease; PR=partial response; SD=stable disease.
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of 22 patients (regardless of CD25 expression) achieved
partial responses. Two of five (40%) patients with low to
normal values of serum IL-2R (sIL-2R) achieved partial
responses, similar to eight of 17 (53%) responding patients
with elevated sIL-2R levels (Fisher’s test P¼0.99). When
baseline sIL-2R levels are considered as a continuous factor
(Wilcoxon’s rank-sum test), the median sIL-2R level of 1,562
(range 857–8,059) was similar to the non-responders with
median of 1,926 (range 28–23,174) (P¼0.84). When lactate
dehydrogenase, a surrogate marker of LCT, was similarly
considered, the medians were almost statistically different
between responding patients (median 593, range 229–1,479)
and non-responders (median 803, range 462–1,580) (P-
value¼0.06).
DISCUSSION
In this study, we determined the prevalence of CD25 and
CD30 expression within patients’ lesions by clinical status
(TNM) and histology, and asked if high expression of CD25 is
predictive of response to denileukin diftitox therapy. We also
developed and tested a frozen- and fixed-tissue assay carried
out locally to measure CD25 expression. High expression of
CD25 (defined as staining of X20% of epidermotrophic
T-cells) was associated with a 78% response rate to denileukin
diftitox therapy in our patients, regardless of whether we used
a fixed- or frozen-tissue assay (Table 3a). The response in
patients with highest CD25 expression staining at our
laboratory was considerably higher than the response rate
of 30% reported in patients receiving at least three prior
therapies in the phase II trial (Olsen et al., 2001). In the
pivotal trial, only patients with 420% CD25 expression,
determined by a reference lab assay, were allowed to enroll
and this group had an overall response rate of 30%. In the
pivotal trial, a number of patients stopped therapy early for
adverse events and were not evaluated for response, which
may explain the low response rate. In our study, patients with
lowest CD25 expression in their lesions had a response rate
of 20%, not different from the pivotal trial response rate
of 30%.
The sensitivity of the currently available commercial
assays for measuring expression of CD25 and for predicting
response to denileukin diftitox has not been well established
(Olsen et al., 2001). The use of a paraffin-embedded, fixed-
tissue IHC assay for detection of CD25 and correlation to
response has not been established. Among 16 lesions that
were bisected and submitted to our lab and to the reference
lab, CD25 expression level was found to be the same in only
seven of 16 specimens: five both low and two both high
CD25 expression. The other nine lesions’ staining results
were discordant. The number of patients treated with
denileukin diftitox with double biopsy results (n¼ 16) was
too low for a correlation. Of five who received denileukin
diftitox, two patients had partial responses with positive
staining by reference lab, and three patients had stable
disease with only one positive by the reference lab. High
CD25 expression, whether determined locally by either a
fixed- or frozen-tissue method, or by the official reference
lab, may be helpful to identify patients who will respond to
denileukin diftitox therapy. No association was possible
between soluble IL-2 receptor levels and response.
In normal T-cells, CD25 is expressed as an activation
marker following cytokine stimulation and is also present on
NK cells at low levels (Nakarai et al., 1994). CD4þCD25þ
T cells or regulatory (T-reg) cells play an important role in
promoting tolerance and prevent naı¨ve T-cells from rejecting
allographs (Lee et al., 2004). In a different study comparing
skin, blood, and nodes, we found that CD25 expression is
highly labile and may be positive in epidermis, down-
regulated in dermis, and extensively downregulated in lymph
node. Thus, CD25 may be dependent on the microenviron-
ment (Jones et al. 2004). Among T-cell tumors, CD25 is
strongly expressed by adult T-cell leukemia/lymphoma and
some lymphoblastic leukemia/lymphoma cases and is more
variably expressed in other T-cell tumor types.
Based on the evaluation of skin biopsies taken from 112
patients with CD4þ CTCL (MF or SS), we found that high
CD25 expression was present in only 22% of all CTCL
patients’ biopsies. Surprisingly, significant CD25 expression
was present in tumor cells in skin biopsies from patients with
all T stages of CTCL, whereas expression of the activation
marker CD30 at 410% was confined to T3 or T4. We
previously reported that histologic progression is a poor
prognostic feature, especially if it occurs within 2 years of
Table 3c. Comparison of CD25 expression level
between reference and local laboratory in 16 patients’
bisected biopsy specimens
Reference lab
result
MDACC
fixed low
MDACC
frozen low
MDACC
fixed high
MDACC
frozen high
Low CD25, o20% 3 2 3 0
High CD25, 420% 4 2 1 1
MDACC=MD Anderson Cancer Center.
Lesional skin biopsies were bisected and processed by frozen or fixed
assays locally and at the same time analyzsed by a fresh-tissue method at
the reference laboratory.
Underlined numbers represent the concordant results.
a b
Figure 4. Loss of CD25 expression in Se´zary patient’s lesion with large-cell
transformation (a) before and (b) after three cycles of denileukin diftitox
treatment (original magnification:  1,000). (a) A 72-year-old black male
(patient 12) with Se´zary Syndrome (T4LN0B2M1) had 75% CD25 expression
in lesional T-cells in his initial skin biopsy. (b) He initially responded to
denileukin diftitox, but after three cycles, repeat skin biopsy showed 5%
CD25 expression in lesional T-cells. He had disease progression at course 6
and subsequently received bexarotene.
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diagnosis (Stefanato, 1998; Diamandidou et al., 1999). High
CD25 expression in epidermal T-cells was significantly
associated with advanced T status and with histological
LCT. This supports a previous study, which demonstrated that
increased CD25 expression is a feature of LCT in a subset of
MF cases (Waters et al., 1990). High expression of CD25 in
CTCL may also identify a subset of patients who have or will
undergo LCT.
Foss et al. (2001) have reported higher response rates to
denileukin diftitox of 60% among patients given higher doses
of steroids to block acute infusion reactions. In a recent, small
phase I trial, Foss et al. (2005) further suggested that oral
bexarotene may upregulate CD25 expression in peripheral
blood mononuclear cells and increase sensitivity to dinileu-
kin diftitox therapy. Although our patients received steroids,
only very low doses of 10 mg of prednisone were given
before daily infusions and probably did not influence the
response rate, and certainly did not block vascular leak
syndrome. In 15 patients’ lesions studied before and after the
start of oral bexarotene therapy, CD25 expressed in only four
patients’ skin lesions. The greatest change (from 1 to 35%)
was in one bexarotene complete responder, and nine did not
have significant changes in expression levels before and after
bexarotene.
In summary, our data suggest that high expression of CD25
as measured by either fixed- or frozen-tissue IHC assay carried
out locally may predict a higher likelihood of clinical response
to denileukin diftitox, and that high serum levels of the soluble
sIL-2R do not block response. Additional assays (i.e. PCR) to
measure expression of CD25 or other chains of the IL2-R on
tumor cells should be evaluated to select and follow patients
on denileukin diftitox. These results support the need for the
current ongoing large multi-center study correlating CD25
expression with response to denileukin diftitox.
MATERIALS AND METHODS
Patients
All MF and SS patients evaluated at MD Anderson Cancer Center
between 1999 and 2001 were prospectively studied for the
expression of activation markers CD25 and CD30 performed at the
time of initial evaluation. All patients signed an Institutional Review
Board-approved consent to allow extra tissue from skin biopsy
specimens to be used for research purposes. The study was
conducted according to the Declaration of Helsinki Principles.
Forty-eight individuals had newly diagnosed MF or SS. Fifty-four,
recently diagnosed patients had the same baseline stage, but had
received skin-directed treatment (topicals or UVB therapy) without
change in T stage. At the time of skin biopsy, 11 T1 patients had
progressed from T1 to T3 (n¼ 6), or T4 (n¼ 4) (Table 1). MF and SS
patients’ clinical status was assessed using the TNM system (Bunn
et al., 1980; Heald, 2003) with the additional criteria that blood
involvement defined as 430% CD4þCD26 by flow cytometry
(Washington et al., 2002) at baseline was considered as stage IVA
and bone marrow involvement as stage IVB. All patients had
negative serology for human T lymphotropic virus-1 and HIV at the
time of initial staging.
Twenty-four patients were evaluated for CD25 expression with
respect to response to denileukin diftitox. Patients were assessed for
clinical response using a skin-weighted assessment tool to calculate
the percent body surface area with patch, plaque, tumor, or
erythema (Olsen et al., 2001). Partial response required 450%
improvement in skin score from baseline assessment without
increase in blood or nodes for one cycle and complete response
required clearing of all clinical lesions and nodes. Flow cytometry
was also performed to assess atypical clones in blood. Eligibility
criteria to receive denileukin diftitox included histologically
confirmed persistent or recurrent CTCL, a serum albumin level of
3 g/dl or more, and determination of the level of CD25 expression by
IHC on lesional skin biopsy.
Histology and IHC
All skin biopsy specimens in the study were reviewed by a single
hematopathologist (DJ) to confirm the diagnosis, using World Health
Organization classification criteria (Jaffe et al., 2001). The study was
limited only to CTCL cases with a CD4þ T-cell immunophenotype
including MF (n¼ 100) and SS (n¼ 13). MF was characterized by
patches, plaques, and/or tumors with epidermotropic helper/
memory tumor cells. Diagnosis of early MF required pleomorphic,
persistent skin lesions with epidermotrophism of atypical cells on
biopsy. Twenty-nine of 33 stage IA patients skin biopsies were
evaluated for T-cell receptor clonality in skin lesions by amplifica-
tion of the V-g chain and 13 biopsy specimens were positive.
SS was defined as 480% erythroderma and a demonstrable
leukemic T-cell component as determined by peripheral smear and
flow cytometry (Vonderheid et al., 2002). Primary SS (presenting de
novo without MF lesions) had tumor cells, lacking epidermotropism
and largely confined to perivascular dermis, as described recently
(Diwan et al., 2005). Erythrodermic patients (T4) were further
classified by the TNM staging as III (no nodes) or IVA (nodes
involved by biopsy or 41,000 Se´zary cells), or as IVB (bone marrow
or visceral involvement). Cases with more than 25% large tumor
cells were arbitrarily defined as LCT by histology. Surrogate markers
including lactate dehydrogenase, b2-microglobulin, and soluble
serum IL-2 were also determined in each patient (Wasik et al., 1996;
Diamandidou et al., 1999). Intermediate histological progression
was diagnosed in those cases with 10–24% large cells.
Immunostaining was performed on paraffin-embedded formalin-
fixed or fresh–frozen sections skin biopsies using avidin–biotin-
conjugated reagents (LSABþ ; Dakocytomation, Carpinteria, CA)
with the antigen–antibody reaction visualized using 3-amino-
9-ethylcarbazole as described previously (Jones et al., 2004).
Antibodies used were mouse monoclonal antibodies directed against
CD25 (4C9; Novocastra, Newcastle-Upon-Tyne, UK) and a poly-
clonal CD3 antisera (Dakocytomation). Heat-induced epitope
retrieval was conducted in a steamer with citrate pH 6.0 buffer for
paraffin section staining. The percentage of CD3þ T-cells positive
for CD25 were counted at  400 magnification by eye and scored
into the following groups: 0–5, 5–10, 10–20, 20–50%, or more than
50% CD25 positivity. For the purpose of statistical analysis, lesions
with more than 20% CD25þ lymphocytes were regarded as
positive. Immunostaining was performed with mouse monoclonal
antibodies directed against CD30 (BerH2; Dako, Carpinteria, CA).
Antigen retrieval was performed in a microwave with Dako target
retrieval buffer. Staining was performed using a Dako auto-
stainer with biotin–avidin–peroxidase-conjugated reagents (Dako)
and 3-amino-9-ethylcarbazole as the chromogenic substrate. CD30
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staining was considered as having positive expression if 410% of
the lymphocytes were positive.
Soluble IL-2R
Serum soluble IL-2R levels were analyzed by enzyme immunoassay
performed by Nichols Institute/Quest Diagnostics (San Juan Capis-
trano, CA). The level of sIL-2R has been previously shown to
correlate with CTCL tumor burden (Wasik et al., 1996). Pre-sIL-2R
levels were assessed for relation with CD25 expression and response
to denileukin diftitox treatment. The normal values were defined as
200–1,100 U/ml and 41,100 as above normal.
Statistical analysis
Scatter plots were used to investigate the association between
histology, clinical status, and expression of CD25 and/or CD30 in
lesional skin biopsies. w2 or Fisher’s exact test was used to test for
independence between two categorical variables. The weighted k
coefficient was used to measure agreement among measurement
methods. Values 40 indicate agreement greater than chance, values
o0.75 typically indicate agreement, and valueso0.40 suggest poor
agreement beyond chance. All P-values are two-sided and the test is
considered significant if P-value is less than 0.05. Statistical analyses
were carried out using S-Plus 6.0.
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